Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroinflammation and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNK13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | KCNK13 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and patch clamp validation. |
View KCNK13 Products |
| Benchmark Ab | Anti-KCNK13 Recombinant Antibody Sequence verified positive control for flow cytometry and IHC. |
View KCNK13 Products |
| Validator | KCNK13 siRNA Set For knockdown verification in primary microglia. |
View KCNK13 Products |
| Related Target A | KCNK12 (THIK-2) Closest homolog for selectivity and counter-screening assays. |
View KCNK12 Products |
| Related Target B | P2RX7 Synergistic microglial target regulating neuroinflammation. |
View P2RX7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 4-TM Channel | Lentivirus-driven stable cell lines ensure native folding for patch-clamp and flux assays. |
| Selectivity over Homologs (THIK-2) | KCNK12 (THIK-2) control reagents available for off-target counter-screening. |
| Lack of Controls | Recombinant positive control antibodies included |
| False Positives | Validated siRNA included for target knockdown specificity checks |
Live KCNK13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNK13 (THIK-1) therapeutics is intensifying, with major players shifting focus from broad immunosuppression to microglia-targeted modulation. As first-generation small molecule inhibitors enter preclinical and early clinical validation for neurodegenerative diseases like Alzheimer's, the next wave of R&D is targeting highly selective channel blockers that spare other K2P channels.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Neuro-biotechs, Academic spin-offs | Alzheimer's Disease, Stroke, Neuroinflammation | High-throughput Potassium Flux Assay (Need Lentivirus for Stable Cell Line) |
| Small Molecule Activators | Psychiatric drug developers | Depressive disorders, Neuroprotection | Patch Clamp Validation (Need Sequence Verified Cell Lines) |
| Monoclonal Antibodies | Target-specific antibody developers | Neuro-oncology, Microglial modulation | Conformational Epitope binding (Need Native Glycosylation / Cell Surface Expression) |